Bioxodes closes €12 million in Series A funding round | Bioxodes
Summary
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023 Gosselies, Belgium, November 21, 2023 Bioxodes SA, a biopharmaceutical company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces 12 million ($13M) in a Series A funding from historic investors. This new funding will allow Bioxodes to continue the clinical development of its main drug candidate, Ir-CPI, for patients with intracerebral hemorrhage (ICH), right through to the end of phase IIa. The company also intends to use the proceeds to pursue new preclinical R&D work into the effect of Ir-CPI on neutrophils, which are key components in the neuro-inflammatory process. Our aim now is to keep our clinical development program moving forward by launching plans for our phase IIb efficacy trial, which is scheduled for 2025. Derived from a ticks saliva, this product could become the first injectable antithrombotic drug suitable for use in patients within the first 72 hours of intracerebral hemorrhage.
Funding
Review available funding amount, funding date, investors, and linked company information related to Bioxodes closes €12 million in Series A funding round | Bioxodes in the interactive ISVWorld profile.